From conventional to convenient: Blood microsampling in metabolomics

Join us to explore blood microsampling in untargeted and targeted metabolomics, its key advantages and the need for validation against traditional sampling methods.

Metabolomics, the large-scale study of metabolites within biological samples, is rapidly advancing as a key tool in clinical diagnostics and personalized medicine. However, such field of research often involves large-scale studies, multi-center sample collection, or longitudinal follow-up of subjects, which often generate limitations associated with sample collection, handling, and stability. To overcome challenges in traditional blood sampling, blood microsampling has emerged as a promising alternative, offering practical and logistical advantages. However, to fully integrate microsampling into untargeted metabolomics, further research is needed to validate its performance and ensure reliable metabolite profiling comparable to conventional sampling methods.

Of interest to:

Clinical researchers looking to integrate metabolomics into patient‑centered studies.
Laboratory scientists exploring innovative blood collection and analysis techniques.
Healthcare professionals interested in emerging tools for personalized medicine.
Biotech and pharma teams developing metabolomics‑driven diagnostics or therapeutics.
Academics and students eager to stay at the forefront of metabolomics and microsampling research.

Your details

By submitting this form you are agreeing to our Terms & Conditions and Privacy Policy, and agree to receiving relevant emails from The Evidence Base about the latest news and editorial features.

Terms & Conditions

I agree to receive third party emails to keep me informed of relevant products and services relevant to my industry.

I agree for my registration data to be transferred to the lead partner organization (PCSIG).

Subscribing to

Confirm sign-up

What you will learn:

Metabolomics explained: What it is and how it can drive innovation and improve clinical practice.
Key challenges: The current hurdles in metabolomics and strategies to overcome them.
Sampling insights: Advantages and limitations of blood microsampling versus conventional methods.
Emerging solutions: Cutting‑edge quantitative microsampling technologies addressing the limitations of current clinical practices.

Speaker:

Michael Witting
Co-Head Metabolomics and Proteomics Core
Helmholtz Zentrum München, Germany

Dr Michael Witting is a trained analytical chemist and holds a PhD from the Technical University of Munich. In 2021 he started as Co-Head of the Metabolomics and Proteomics Core, Helmholtz Munich, leading the metabolomics team. His research interest is the development of novel analytical and data analytical methods for metabolomics analysis of different matrices, including blood microsamples, such as DBS. Together with Dr Helen Gika he coordinates the EU-funded HUMAN doctoral network exploring new ways for metabolomic analysis of blood and blood microsamples.

Moderated by:

Neil Spooner
Founder, Patient Centric Sampling Interest Group

Located in Hertford, UK, Neil is the Chair and co-founder of the PCSIG. He also runs a consultancy company where one of the main drivers is to help Clients understand the benefits of patient centric blood sampling, develop appropriate technologies and workflows and implement them for the benefit of human wellbeing. Neil’s interest in these technologies began in 2007 whilst leading efforts at GlaxoSmithKline to find blood sampling and analysis approaches suitable for the measurement of pharmaceutical concentrations in samples obtained from children.

Share this webinar